Dr. John Cush RheumNow
2 years 6 months ago
In Jan 2024 Drug prices rose for more than 900 meds, w/ average price increase ~4.7% (slightly lower vs prior 5 yrs). Main Rheum Drugs included Autoimmune disease medications rose 5% for Enbrel, 6% for Xeljanz and ~4.8% for Stelara https://t.co/cnMxhvBKKd https://t.co/DqF4IaXRWW
Dr. John Cush RheumNow
2 years 6 months ago
Resolvin (RvT)4 - orchestrates macrophage responses to limit atherosclerosis during inflammatory arthritis. (RvT)4 negatively correlates w/ vascular lipid load in inflammatory arthritis; RvT4 can be used to reduce blood vessel inflammation. https://t.co/H38cFvDcvE https://t.co/ptZpjWf1F6
Dr. John Cush RheumNow
2 years 6 months ago
VITAL Study - Autoimmune Prevention Requires Continued Supplements
https://t.co/jXTq11R8fE https://t.co/QaCGBdAMAj
The NEJM has published the results of the FRONTIER 1 trial demonstrating the efficacy of JNJ-77242113, an oral interleukin-23 (IL-23) receptor antagonist peptide, in patients with psoriasis (PSO).
Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".
Dr. John Cush RheumNow
2 years 6 months ago
JAMA Clinical Challenge - Recurrent Fever, Rash, and Shortness of Breath in a 69-Year-Old. Admited with fever, fatigue, rash, right periorbital swelling, SOB, Palpable purpural, Serositis previously - whats your diagnosis? https://t.co/AP0Df8vIWx https://t.co/57UtHqXjAf
Dr. John Cush RheumNow
2 years 6 months ago
Many #RA pts remain on Steroids despite b/tsDMARD use! Study 228 #RA pts, 68% Rx low-dose GCs (32% no GCs). After 3 yrsof b/tsDMARDs, 32% still on GCs, 23% D/C GCs, & 20% go on & off, 25% never took GCs. GCs use assoc w/ HTN (20 v 11%) & MI (2.3% vs 0) https://t.co/lWVfvJrAyp https://t.co/uTIWqDAjRG
Refractory of difficult to treat (D2T-RA) rheumatoid arthritis (RA) comprises a minority of patients that can be categorized by clinical and imaging parameters to formulate a better therapeutic approach.
Inflammatory arthritis (IA) is a common manifestation in systemic sclerosis (SSc), affecting nearly one-third of patients.
A prospective study of SSc patients enrolled in the Australian Scleroderma Cohort Study assessed the frequency and the associations of IA with SSc and serological parameters.
Dr. John Cush RheumNow
2 years 6 months ago
649 # RA pts (291 ACPA+) from the Leiden Early Arthritis Clinic shows Disease activity incr by:
- Obesity: + 0.32 higher DAS
- Obese + ACPA+: + 0.43 DAS
- ACPA+ RA: SJC incr 60%, TJC 55%, CRP + 3.7 mg/L https://t.co/WH0tpybe4a https://t.co/jkgDLQdfRH
Dr. John Cush RheumNow
2 years 6 months ago
Determinants of Gout Flares
Approximately 12 million US adults in the US have gout. Two recent literature reports highlight contributors to gout flares.
https://t.co/xAUyBsJVz9 https://t.co/bEo10XJ9qv
Dr. John Cush RheumNow
2 years 6 months ago
J&J announced the results of Phase 2 DAHLIAS study of nipocalimab in Sjögren’s; w/ a signif reduction in clinESSDAI at week 24 vs placebo. Nipocalimab is an investigational anti-FcRn treatment being studied in RA, & myasthenia gravis https://t.co/L7WNtdii8N https://t.co/Ro6UoPT2fR
In the 2 years that followed the termination of the VITAL study, the preventative effect of vitamin D on incident autoimmune disease disappeared with supplement discontinuation; but n-3 fatty acid treated individuals had a sustained benefit in reducing the risk of autoimmune disease.
Dr. John Cush RheumNow
2 years 6 months ago
Acute CPPD at significantly higher risk of fractures. 1148 acute CPPD pts matched to 3730 comparators(mean 73 yrs old); Steroids and OP more in CPPD pts. Fx risk was twice as high in the acute CPPD pts (HR 1.8;1.3, 2.3). Fx risk highest forwrist (HR, 3.6) https://t.co/25EOzXI0sH https://t.co/c1Xiq8TaUP
